Haoxi Health Technology Ltd (NASDAQ:HAO) ("Haoxi" or the "Company"), today announced that it has entered into a definitive agreement with certain investors for the purchase and sale of an aggregate of 10,000,000 of the Company’s Class A Ordinary Shares, par value $0.32 per share (the "Shares") (or pre-funded warrants in lieu thereof) at a purchase price of $0.40 per share in a registered direct offering. The purchase price for the pre-funded warrants is identical to the purchase price for Shares, less the exercise price of $0.33 per share.

The aggregate gross proceeds to the Company of this offering are expected to be approximately $4 million. The transaction is expected to close on or about July 13, 2026, subject to the satisfaction of customary closing conditions.

Univest Securities, LLC is acting as the sole placement agent.